β受体阻滞剂与血管紧张素Ⅱ受体阻滞剂联合治疗慢性心力衰竭的疗效观察

β-receptor blockers and angiotensin receptor blockers Ⅱ in the treatment of chronic heart failure

目的探讨β受体阻滞剂与血管紧张素Ⅱ受体阻滞剂(ARB)联合治疗慢性心力衰竭(CHF)的疗效。方法给予基础心脏病治疗和心衰的常规治疗,β受体阻滞剂组加β受体阻滞剂,ARB组加ARB,ARB+β受体阻滞剂组加ARB和β受体阻滞剂。结果在改善心脏结构和心功能,减少住院次数和心率,ARB+β受体阻滞剂组疗效优于β受体阻滞剂组和ARB组,差异均有统计学意义(P<0.05)。结论β受体阻滞剂与ARB联合治疗CHF,能更好地预防心脏重构,改善心功能,减少CHF患者临床事件的发生。

[Objective] To study the effect of β- receptor blockers and angiotensin lI blockers （ARB） in the treatment of chronic heart failure （CHF） patients. [Methods] Each group is given basic treatment of heart disease and conventional treatment of heart failure. The β- receptor blocker group and ARB group and ARB ＋ β- receptor blocker group are respectively given β- receptor blocker agent, ARB agent, β-receptor blocker agent and ARB agent. [Results] The effect in improving the cardiac structure and cardiac function and reducing the number of hospitalization and heart rate of ARB ＋ β- receptor blocker group is better than that of the β- receptor blocker group and the ARB group, and the differences were statistically significant （P 〈0.05）. [Conclusion] ARB ＋ β- receptor blocker in the treatment of CHF can well prevent heart remodeling and improve cardiac function and reduce occurrence of clinical events in patients with CHF.